Larimar Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -87 | |||
EBITDA | -32,720 | -29,549 | -62,411 | -47,624 |
EBIT | -32,782 | -29,613 | -62,498 | -47,712 |
Net Income | -32,782 | -29,613 | -62,498 | -47,712 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -44,160 | -44,614 | -38,527 | -28,776 |
Cash | 92,687 | 177,913 | 85,412 | 90,140 |
Basic Shares | 103,882 | 85,182 | 85,182 | 78,324 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -350 | -318 | -311 | -272 |
EBITDA | -165,323 | -80,286 | -36,638 | -36,208 |
EBIT | -165,673 | -80,604 | -36,949 | -36,526 |
Net Income | -165,673 | -80,604 | -36,949 | -34,184 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -43,272 | |||
Free Cash Flow | -113,292 | -71,275 | -33,623 | -27,669 |
Cash | 85,412 | 33,218 | 26,749 | 26,825 |
Basic Shares | 72,947 | 61,256 | 43,901 | 25,761 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.30 |
2026-03-31 | -$0.31 |
2025-12-31 | -$0.73 |
2025-09-30 | -$0.61 |